These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28711661)

  • 1. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
    Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
    Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic role of nitrergic neurotransmission in mood disorders.
    Ghasemi M; Claunch J; Niu K
    Prog Neurobiol; 2019 Feb; 173():54-87. PubMed ID: 29890213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.
    Henter ID; de Sousa RT; Gold PW; Brunoni AR; Zarate CA; Machado-Vieira R
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):153-166. PubMed ID: 27781556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic Modulators in Depression.
    Henter ID; de Sousa RT; Zarate CA
    Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel glutamatergic drugs for the treatment of mood disorders.
    Lapidus KA; Soleimani L; Murrough JW
    Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
    Hashimoto K; Malchow B; Falkai P; Schmitt A
    Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):367-77. PubMed ID: 23455590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets.
    Lang E; Mallien AS; Vasilescu AN; Hefter D; Luoni A; Riva MA; Borgwardt S; Sprengel R; Lang UE; Gass P; Inta D
    Neurosci Biobehav Rev; 2018 Jan; 84():352-358. PubMed ID: 28843752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
    Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
    Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood disorders: regulation by metabotropic glutamate receptors.
    Pilc A; Chaki S; Nowak G; Witkin JM
    Biochem Pharmacol; 2008 Mar; 75(5):997-1006. PubMed ID: 18164691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests.
    Andreasen JT; Gynther M; Rygaard A; Bøgelund T; Nielsen SD; Clausen RP; Mogensen J; Pickering DS
    Neurosci Lett; 2013 Jun; 546():6-10. PubMed ID: 23643996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment.
    Li ML; Yang SS; Xing B; Ferguson BR; Gulchina Y; Li YC; Li F; Hu XQ; Gao WJ
    Exp Neurol; 2015 Nov; 273():190-201. PubMed ID: 26341392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test.
    Ostadhadi S; Norouzi-Javidan A; Chamanara M; Akbarian R; Imran-Khan M; Ghasemi M; Dehpour AR
    Brain Res Bull; 2017 Sep; 134():136-141. PubMed ID: 28754288
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ahmed H; Haider A; Ametamey SM
    Expert Opin Ther Pat; 2020 Oct; 30(10):743-767. PubMed ID: 32926646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.